Key result
The addition of admission venous lactate level to the GRACE 2.0 score significantly improved the prediction of 30-day mortality in STEMI patients treated with primary PCI.
Why the study?
Conventional STEMI risk predictors may be altered by treatment without reflecting microcirculation, prompting investigation into whether venous lactate adds prognostic value to the GRACE 2.0 model.
Does the addition of admission venous lactate level to the GRACE 2.0 score improve the prediction of 30-day all-cause mortality in STEMI patients treated with primary PCI?
Observational (n=323)
No
Does the addition of admission venous lactate level to the GRACE 2.0 score improve the prediction of 30-day all-cause mortality in STEMI patients treated with primary PCI?
Answers are grounded in this paper and cite their sources.
Admission venous lactate level provides independent and additive prognostic value to the GRACE 2.0 score for predicting 30-day mortality in STEMI patients undergoing primary PCI.
BACKGROUND: In many of the risk estimation algorithms for patients with ST-elevation myocardial infarction (STEMI), heart rate and systolic blood pressure are key predictors. Yet, these parameters may also be altered by the applied medical treatment / circulatory support without concomitant improvement in microcirculation. Therefore, we aimed to investigate whether venous lactate level, a well-known marker of microcirculatory failure, may have an added prognostic value on top of the conventional variables of the "Global Registry of Acute Coronary Events" (GRACE) 2.0 model for predicting 30-day all-cause mortality of STEMI patients treated with primary percutaneous coronary intervention (PCI). METHODS: In a prospective single-center registry study conducted from May 2020 through April 2021, we analyzed data of 323 cases. Venous blood gas analysis was performed in all patients at admission. Nested logistic regression models were built using the GRACE 2.0 score alone (base model) and with the addition of venous lactate level (expanded model) with 30-day all-cause mortality as primary outcome measure. Difference in model performance was analyzed by the likelihood ratio (LR) test and the integrated discrimination improvement (IDI). Independence of the predictors was evaluated by the variance inflation factor (VIF). Discrimination and calibration was characterized by the c-statistic and calibration intercept / slope, respectively. RESULTS: Addition of lactate level to the GRACE 2.0 score improved the predictions of 30-day mortality significantly as assessed by both LR test (LR Chi-square = 8.7967, p = 0.0030) and IDI (IDI = 0.0685, p = 0.0402), suggesting that the expanded model may have better predictive ability than the GRACE 2.0 score. Furthermore, the VIF was 1.1203, indicating that the measured lactate values were independent of the calculated GRACE 2.0 scores. CONCLUSIONS: Our results suggest that admission venous lactate level and the GRACE 2.0 score may be independent and additive predictors of 30-day all-cause mortality of STEMI patients treated with primary PCI.
No takes yet. Share an insight, caveat, or question.
Szabó et al. (2022) conducted an observational in ST-elevation myocardial infarction (STEMI) (n=323). Admission venous lactate level vs. GRACE 2.0 score alone was evaluated on 30-day all-cause mortality (IDI 0.0685, 95% CI 0.0031 to 0.1338, p=0.0402). The addition of admission venous lactate level to the GRACE 2.0 score significantly improved the prediction of 30-day mortality in STEMI patients treated with primary PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: